| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 3
Formulation and optimization: Liquisolid of domperidone for solubility enhancement
1 Guru Jambheshwar University of Science and Technology, Departmental of Pharmaceutical Sciences, Hisar, 125001, India2 Om Sterling Global University, School of Pharmaceutical Sciences, Hisar, 125001, India
DOI : 10.23893/1307-2080.APS6234 Viewed : 2176 - Downloaded : 494 In the present study, liquisolid formulations of domperidone were prepared using Tween 80, microcrystalline cellulose, Aerosil 200 as solvent, carrier, and coating material, respectively. 2-factors, 3-level central composite experimental design was employed to examine the effect of independent variables (excipient ratio and load factor) on dependent variables (solubility and drug content). Differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray powder diffraction (XRD) and scanning electron microscopy (SEM) studies were utilized to characterize the optimized formulation. The results of solubility studies of different batches of liquisolid formulations revealed an improvement in solubility ranging from 17.02-58.10 µg/mL as compared to pure drug domperidone (7.47 µg/mL). The in-vitro dissolution profile of optimized batch of liquisolid formulation depicted higher rate of drug release (93.63%) when compared with conventional marketed tablets (Dompy®, 81.98%) following non fickian diffusion (n<0.5) as mechanism of drug release from the matrix. Keywords : liquisolid, domperidone, solubility enhancement, optimization